Is It Too Late to Buy Coronavirus Biotech Stocks?
A handful of biotech companies have been stock-market winners even as the coronavirus outbreak has pushed the market as a whole into bearish territory. The S&P 500 is down 25% since the start of the year, while Moderna (NASDAQ: MRNA) has gained 47%, Regeneron Pharmaceuticals (NASDAQ: REGN) rose by 34%, Gilead Sciences (NASDAQ: GILD) climbed by 24%, and Inovio Pharmaceuticals (NASDAQ: INO) soared by 96%.
There is no secret to these companies' short-term performance. Each one is working on a treatment or vaccine for coronavirus, the pandemic that so far has resulted in more than 207,000 cases of COVID-19 worldwide. Now investors are wondering: Considering the gains, is it too late to buy shares of these companies?
Image source: Getty Images.
Source Fool.com
